AbbVie opens biologics plant in Singapore, completing $320m project

By Dan Stanton contact

- Last updated on GMT

The site in Tuas, Singapore. Image c/o AbbVie
The site in Tuas, Singapore. Image c/o AbbVie

Related tags: Steel, Cell, Cell culture

AbbVie has opened a mammalian cell culture-based drug manufacturing facility equipped with both stainless and single-use equipment, as part of a $320m investment in Singapore.

The $320m (€274m) investment announced in 2014​ marked AbbVie’s first manufacturing venture in Asia. And just over a year on from the opening of a small molecule API plant​ at the 120,000m2​ site in Tuas, Singapore, the firm has opened its biologics manufacturing facility.

“We indicated expectations to be operational by 2018,”​ AbbVie’s director at the Singapore site Marc O'Donoghue told Biopharma-Reporter. “The opening this week is on schedule with validations ongoing.”

He added the mammalian cell culture facility will be used for both clinical and commercial supply and has a mix of single use and stainless steel equipment.

Between the small and large molecule plants, AbbVie will employ 250 staff in Singapore to support its global immunology and oncology products.


With a small and large molecule production facility now open, there is scope to make antibody-drug conjugates (ADC) in Singapore, something discussed when the ground was broken at the site.

According to AbbVie: “Our strength in discovering and developing highly specific monoclonal antibodies and our experience in small molecule chemistry and analytics make ADCs a strong focus area of development for AbbVie.”

AbbVie has a partnership with a partnership with Seattle Genetics, for access to its pyrrolobenzodiazepine (PBD) dimer ADC technology and EC-mAb site-specific conjugation technology, and last year​ added a stem-cell based ADC to its pipeline through the $5.8bn acquisition of Stemcentrix.

Related news

Related products

show more


Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers